Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy MEI Pharma stock

Own MEI Pharma stock in just a few minutes.

MEI Pharma, Inc is a biotechnology business based in the US. MEI Pharma shares (MEIP) are listed on the NASDAQ and all prices are listed in US Dollars. MEI Pharma employs 51 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in MEI Pharma

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – MEIP – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

MEI Pharma share price

Use our graph to track the performance of MEIP stocks over time.

MEI Pharma shares at a glance

Information last updated 2021-04-22.
52-week range$2.37 - $4.54
50-day moving average $3.53
200-day moving average $3.21
Wall St. target price$9.67
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.75

Buy MEI Pharma shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy MEI Pharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is MEI Pharma under- or over-valued?

Valuing MEI Pharma stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of MEI Pharma's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

MEI Pharma's PEG ratio

MEI Pharma's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 20.6. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into MEI Pharma's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

MEI Pharma financials

Revenue TTM $39.7 million
Gross profit TTM $26.2 million
Return on assets TTM -13.9%
Return on equity TTM -48.22%
Profit margin -91.45%
Book value $0.65
Market capitalisation $380.3 million

TTM: trailing 12 months

Shorting MEI Pharma shares

There are currently 10.6 million MEI Pharma shares held short by investors – that's known as MEI Pharma's "short interest". This figure is 9% up from 9.7 million last month.

There are a few different ways that this level of interest in shorting MEI Pharma shares can be evaluated.

MEI Pharma's "short interest ratio" (SIR)

MEI Pharma's "short interest ratio" (SIR) is the quantity of MEI Pharma shares currently shorted divided by the average quantity of MEI Pharma shares traded daily (recently around 640296.5496368). MEI Pharma's SIR currently stands at 16.52. In other words for every 100,000 MEI Pharma shares traded daily on the market, roughly 16520 shares are currently held short.

However MEI Pharma's short interest can also be evaluated against the total number of MEI Pharma shares, or, against the total number of tradable MEI Pharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case MEI Pharma's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 MEI Pharma shares in existence, roughly 90 shares are currently held short) or 0.0945% of the tradable shares (for every 100,000 tradable MEI Pharma shares, roughly 95 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against MEI Pharma.

Find out more about how you can short MEI Pharma stock.

MEI Pharma share dividends

We're not expecting MEI Pharma to pay a dividend over the next 12 months.

Have MEI Pharma's shares ever split?

MEI Pharma's shares were split on a 1:6 basis on 18 December 2012. So if you had owned 6 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your MEI Pharma shares – just the quantity. However, indirectly, the new 500% higher share price could have impacted the market appetite for MEI Pharma shares which in turn could have impacted MEI Pharma's share price.

MEI Pharma share price volatility

Over the last 12 months, MEI Pharma's shares have ranged in value from as little as $2.37 up to $4.54. A popular way to gauge a stock's volatility is its "beta".

MEIP.US volatility(beta: 1.49)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while MEI Pharma's is 1.492. This would suggest that MEI Pharma's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

MEI Pharma overview

MEI Pharma, Inc. , a late-stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase II clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome. The company has a license, development, and commercialization agreement with Kyowa Kirin Company; a clinical collaboration with BeiGene, Ltd. ; a license, development, manufacturing, and commercialization agreement with Helsinn Healthcare SA; and license agreements with Presage Biosciences, Inc. and CyDex Pharmaceuticals, Inc.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site